Increasing access to weight-loss drugs could lead to increased employee productivity and retention, the platforms argue.
Growing interest in weight loss drugs is taking on new forms of workplace wellness.
Employers may soon be able to help streamline their staffs thanks to a new partnership between healthcare solutions provider Xevant and telehealth platform Ivim Health to offer an enterprise GLP-1 solution, Ivim at Work (IaW).
While surveys generally show that employees (particularly Gen Z and millennials) prefer employers that support their health and wellness with corporate wellness programs, one surprising survey result this year revealed that 20% of Americans would change jobs for an employer that sponsored Ozempic or Zepbound as a healthcare benefit.
Through this strategic alliance, Ivim Health’s team of certified obesity management experts will ensure employees receive personalized treatment and support, while Xevant will provide access to low-cost GLP-1 from its network of branded and combination weight loss medication suppliers.
“Our partnership with Ivím Health brings an unparalleled level of care, cost, management, choice and corporate wellness solutions to the market,” said Brandon Newman, CEO of Xevant. “By leveraging Xevant’s data analytics and Ivím Health’s clinical expertise, we are confident we can deliver a program that sets a new standard in corporate wellness.”
The program will be available from August 1st.
According to the platform, IaW programs not only save employees money, they are also expected to reduce medical costs, improve health outcomes, and increase productivity and employee retention.
“We are excited to partner with Xevant to introduce ‘Ivím at Work,’ a groundbreaking step in workplace wellness management,” said Anthony Cantor, CEO of Ivim Health. “This program fosters our commitment to providing customized, effective health solutions that significantly improve employee health and reduce healthcare costs.”
The global market for obesity treatments could grow to $100 billion by 2030, according to Goldman Sachs Research.
Recently, JPMorgan Private Capital, the venture capital and growth equity team within JPMorgan Asset Management, raised more than $500 million for a life sciences fund targeting private biotechnology companies with a focus on weight loss drugs.
